Regulatory effects of Astragalus membranaceus polysaccharides on lipid metabolism disorders induced by a high-fat diet in spotted sea bass (Lateolabrax maculatus).

This study evaluated the regulatory effects of Astragalus membranaceus polysaccharides (AMP) on lipid metabolism disorders induced by a high-fat diet (HFD) in spotted sea bass (Lateolabrax maculatus). Compared with the normal diets (10 % lipids), diets containing 15 % lipid levels were used as the high-fat diet (HFD). Three levels of the AMP (0.06 %, 0.08 %, 0.10 %) were added in the HFD and used as experimental diets. A total of 375 spotted sea bass (average weight 3.00 ± 0.01 g) were divided into 15 tanks and deemed as 5 groups, with each tank containing 25 fish. Fish in each group were fed with different diets for 56 days. After feeding, the HFD induced lipid metabolism disorders in fish, as evidenced by elevated serum lipids, malonaldehyde levels, and more severe liver damage. The AMP alleviated the HFD-induced liver damage, as evidenced by the reduced severity of liver histological lesions and malonaldehyde levels. The low-density lipoprotein cholesterol was reduced, and the expression of FAS and PPAR-α were down and up-regulated, respectively. However, the AMP had a limited ability to affect the serum lipids and abdominal fat percentage. These results reveal the potential of the AMP used in aquaculture to regulate lipid metabolism disorders induced by the HFD.

Regulatory patterns of Chinese patent medicine for lipid metabolism disorders in patients with type 2 diabetes mellitus complicated by ischemic stroke: A systematic review and network meta-analysis.

BACKGROUND: To investigate the regulatory patterns of Chinese patent medicine (CPM) interventions on lipid metabolism disorders in patients with type 2 diabetes mellitus (T2DM) complicated by ischemic stroke. METHODS: Two researchers independently searched 8 major databases and created a comprehensive database containing all randomized controlled trials (RCTs) that investigated the application of "blood-activating and stasis-removing" CPM in the treatment of stroke combined with T2DM until October 1, 2022. The collected data were compiled and organized in Excel. Quality assessment was performed using the Cochrane 5.3 bias risk assessment tool, and the network meta-analysis was conducted using R software. RESULTS: A total of 12 articles were included in the final analysis, covering 4 types of CPM: Naoxintong Capsules (NXT), Tongmai Jiangtang Capsules, Tongxinluo Capsules (TXL), and Yindan Xinnaotong Soft Capsules. Among these, CPM formulations containing herbs with blood-activating and stasis-removing properties were the most commonly used. The results of the network meta-analysis are as follows: (1) the combination of 3 CPM formulations showed superior efficacy in improving total cholesterol levels compared to conventional Western medicine treatment (CT). In particular, Yindan Xinnaotong Soft Capsules + CT (surface under the cumulative ranking curve [SUCRA] = 97.24%) demonstrated the highest efficacy, followed by NXT + CT (SUCRA = 66.23%), and then TXL + CT (SUCRA = 55.16%). (2) TXL + CT treatment exhibited the most promising efficacy in improving triglyceride levels (P < .05), while the effects of the other 3 CPM formulations were not statistically significant. (3) In terms of improving low-density lipoprotein levels, NXT + CT (SUCRA = 82.27%) showed better efficacy than TXL + CT (SUCRA = 73.99%), while the effects of the other 2 CPM formulations were not statistically significant. (4) The combination of CPM formulations and CT resulted in a lower incidence of adverse reactions compared to CT (P < .05). CONCLUSION: The treatment of patients with T2DM complicated by ischemic stroke commonly involved the use of "blood-activating and stasis-removing" herbal medicines. These herbal medicines have shown effectiveness in regulating patients' blood lipid levels. However, it is crucial to acknowledge that the analysis was influenced by variations in the number and quality of RCTs involving different CPM formulations. Therefore, additional validation through large-scale, high-quality RCT studies is required.

Alteraciones del metabolismo lipídico producidas por el virus de la hepatitis C en pacientes con infección crónica / Lipid metabolism alterations produced by hepatitis C virus in patients with chronic infection

OBJETIVO: Es conocido que la infección crónica por el virus de la hepatitis C (VHC) genera un perfil lipídico aparentemente favorable. Paradójicamente, estos pacientes presentan un aumento de eventos cardiovasculares concomitantes. Los objetivos de la presente revisión fueron analizar y sintetizar los estudios que indagasen en las modificaciones que produce el VHC sobre el metabolismo lipídico de los pacientes con infección crónica, así como estudiar si esas modificaciones pueden asociarse a episodios posteriores de enfermedad cardiovascular. MÉTODOS: Se realizó una búsqueda bibliográfica en las bases de datos de Medline y Scopus de los artículos publicados desde enero de 2008 hasta febrero de 2019. Se identificaron un total de 901 publicaciones, de las cuales se revisaron 10 estudios que cumplieron con los criterios de inclusión y exclusión propuestos. RESULTADOS: Se encontró que en los pacientes con infección crónica por el VHC estaban disminuidos los niveles de colesterol total y sus fracciones lipídicas. No existió una clara asociación con los niveles de triglicéridos. Además, parecía haber una asociación entre la infección crónica por VHC y un aumento del riesgo de padecer aterosclerosis y de desarrollar enfermedades cardiovasculares. CONCLUSIONES: La infección crónica por el VHC tiene un efecto hipolipemiante y aumenta el riesgo cardiovascular. Se precisan estudios prospectivos que analicen el efecto de las nuevas terapias con antivirales de acción directa sobre el metabolismo lipídico y el riesgo cardiovascular

BACKGROUND: Chronic infection with the hepatitis C virus (HCV) is known to generate an apparently favorable lipid profile. Paradoxically, these patients present an increase in concomitant cardiovascular events. The objectives of the present review were to analyze and synthesize studies that inquired into the changes produced by hepatitis C virus (HCV) in the lipid metabolism of patients with chronic infection, and about whether these modifications can be associated with subsequent episodes of cardiovascular diseases. METHODS: A bibliographic search was carried out in the Medline and Scopus databases of the articles published from January 2008 to February 2019. A total of 901 publications were identified, of which 10 studies that fulfilled the inclusion and exclusion criteria were reviewed. RESULTS: It was found that the levels of total cholesterol and its lipid fractions were decreased in patients with chronic HCV infection. There was no clear association with triglyceride levels. In addition, there seemed to be an association between chronic HCV infection and an increased risk of developing atherosclerosis and cardiovascular diseases. CONCLUSIONS: Chronic HCV infection has a lipid-lowering effect and increases cardiovascular risk. Prospective studies are needed to analyze the effect of new therapies with direct-acting antivirals on lipid metabolism and cardiovascular risk

Microbiota intestinal e risco cardiometabólico: mecanismos e modulação dietética / Intestinal microbiota and cardiometabolic risk: mechanisms and diet modulation

A microbiota intestinal, adquirida no período pós-natal, é composta por grande diversidade de bactérias que desempenham diferentes funções no hospedeiro humano, entre elas a absorção de nutrientes, proteção contra patógenos e modulação do sistema imune. O conteúdo bacteriano intestinal ainda não é totalmente conhecido, mas sabe-se que é influenciado por fatores internos e principalmente externos que modulam sua composição e função. Estudos indicam que a microbiota intestinal difere em indivíduos magros e obesos e ainda naqueles que mantêm hábitos alimentares diferentes. Há evidências de que as relações entre dieta, inflamação, resistência à insulina e risco cardiometabólico são em parte mediadas pela composição de bactérias intestinais. Conhecimentos sobre a microbiota poderão reverter em diferentes estratégias para manipular as populações bacterianas e promover saúde. Esta revisão aborda a relevância do conhecimento sobre o papel de fatores ou padrões alimentares na composição da microbiota, assim como mecanismos fisiopatológicos de doenças metabólicas crônicas e as potencialidades de prebióticos e probióticos sobre o perfil de risco cardiometabólico.

The gut microbiota obtained after birth is composed of a large range of bacteria that play different roles in the human host, such as nutrient uptake, protection against pathogens and immune modulation. The intestinal bacterial content is not completely known, but it is influenced by internal, and mainly by external factors, which modulate its composition and function. Studies indicate that the gut microbiota differs in lean and obese individuals, and in individuals with different food habits. There is evidence that the relationship between diet, inflammation, insulin resistance, and cardiometabolic risk are, in part, mediated by the composition of intestinal bacteria. Knowledge about the gut microbiota may result in different strategies to manipulate bacterial populations and promote health. This review discusses the relevance of understanding the role of dietary factors or patterns in the composition of the microbiota, as well as pathophysiological mechanisms of chronic metabolic diseases, and the potential of prebiotics and probiotics on the cardiometabolic risk profile.

Factores de riesgo cardiovascular en el paciente con infección por VIH / Cardiovascular risk factors in patients with HIV infection

Tras la implantación del tratamiento antirretroviral, el SIDA se ha convertido en una enfermedad crónica en los países desarrollados. El riesgo cardiovascular parece ser algo mayor en los pacientes VIH que en los no infectados. Tras la introducción de la terapia antirretroviral, diversas alteraciones metabólicas se observaron, principalmente relacionadas al perfil lipídico y resistencia a la insulina. Esto se debió al propio VIH, a la terapia antirretroviral y a la elevada prevalencia de factores clásicos de riesgo. Varias líneas de evidencias sugirieron que la aterosclerosis puede ser más frecuente o desarrollarse más rápido en individuos HIV+, especialmente los tratados con las potentes combinaciones de antirretrovirales. Esta novedosa necesidad de abordar el riesgo cardiovascular como parte del cuidado del paciente VIH resalta la importancia de tratar al paciente de forma global...(AU)

After the introduction of the antiretroviral treatment, AIDS has become a chronic disease in developed countries. Cardiovascular risk seems to be a little bigger in HIV patients than in non-infected ones. After introducing antiretroviral therapy, several metabolic disturbances have been observed, related mainly with the lipid profile and insulin resistance. It is due to the same HIV, the antiretroviral therapy and a high prevalence of classical risk facts. Several evidence traces suggest that atherosclerosis may be more frequent or may develop faster in HIV+ individuals, especially in those treated with potent antiretroviral combinations. This new necessity of affronting cardiovascular risk as part of HIV patients care highlights the importance of treating the patient in a global form...(AU)

Factores de riesgo cardiovascular en el paciente con infección por VIH / Cardiovascular risk factors in patients with HIV infection

Tras la implantación del tratamiento antirretroviral, el SIDA se ha convertido en una enfermedad crónica en los países desarrollados. El riesgo cardiovascular parece ser algo mayor en los pacientes VIH que en los no infectados. Tras la introducción de la terapia antirretroviral, diversas alteraciones metabólicas se observaron, principalmente relacionadas al perfil lipídico y resistencia a la insulina. Esto se debió al propio VIH, a la terapia antirretroviral y a la elevada prevalencia de factores clásicos de riesgo. Varias líneas de evidencias sugirieron que la aterosclerosis puede ser más frecuente o desarrollarse más rápido en individuos HIV+, especialmente los tratados con las potentes combinaciones de antirretrovirales. Esta novedosa necesidad de abordar el riesgo cardiovascular como parte del cuidado del paciente VIH resalta la importancia de tratar al paciente de forma global.

After the introduction of the antiretroviral treatment, AIDS has become a chronic disease in developed countries. Cardiovascular risk seems to be a little bigger in HIV patients than in non-infected ones. After introducing antiretroviral therapy, several metabolic disturbances have been observed, related mainly with the lipid profile and insulin resistance. It is due to the same HIV, the antiretroviral therapy and a high prevalence of classical risk facts. Several evidence traces suggest that atherosclerosis may be more frequent or may develop faster in HIV+ individuals, especially in those treated with potent antiretroviral combinations. This new necessity of affronting cardiovascular risk as part of HIV patients care highlights the importance of treating the patient in a global form.